Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescribed drugs’ (INO) inventory in 2025. Inventory forecasts are based mostly on numerous components equivalent to the corporate’s monetary efficiency, trade developments, and total financial situations.
Inovio is a clinical-stage biotechnology firm targeted on growing and commercializing DNA-based immunotherapies for infectious illnesses and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s at the moment in Part 3 medical trials. Inovio additionally has a pipeline of different DNA-based vaccines in improvement for numerous infectious illnesses and most cancers indications.
